Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Operating Expenses (2016 - 2026)

Insight Molecular Diagnostics' Operating Expenses history spans 6 years, with the latest figure at $23.9 million for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 30.07% to $23.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $53.4 million, a 13.51% decrease, with the full-year FY2025 number at $53.4 million, down 13.53% from a year prior.
  • Operating Expenses hit $23.9 million in Q4 2025 for Insight Molecular Diagnostics, up from $11.2 million in the prior quarter.
  • Over the last five years, Operating Expenses for IMDX hit a ceiling of $34.2 million in Q4 2024 and a floor of -$5.8 million in Q1 2023.
  • Historically, Operating Expenses has averaged $10.7 million across 5 years, with a median of $10.7 million in 2025.
  • The widest YoY moves for Operating Expenses: up 416.96% in 2023, down 278.92% in 2023.
  • Tracing IMDX's Operating Expenses over 5 years: stood at $17.8 million in 2021, then plummeted by 34.69% to $11.6 million in 2022, then soared by 38.22% to $16.1 million in 2023, then skyrocketed by 113.06% to $34.2 million in 2024, then plummeted by 30.07% to $23.9 million in 2025.
  • Business Quant data shows Operating Expenses for IMDX at $23.9 million in Q4 2025, $11.2 million in Q3 2025, and $10.2 million in Q2 2025.